Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | EVP, Chief Commercial Officer | August 31, 2026 | August 31, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date August 31, 2026 · Filed August 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,555 |
Ending reported balance
After 2026-08-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-31 · Exercise / conversion · Acquired 10,000 · Balance 68,555 Row 2 · 2026-08-31 · Sale · Disposed 10,000 · Balance 58,555 |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.26 · Expires 2031-03-31 | Direct | 0 |
Reported balance
After 2026-08-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-31 · Exercise / conversion · Disposed 10,000 · Balance 0 F1: Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2022 Filed Mar 3, 2022 21:39 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 31,715 | $37.63 Strike: $37.63 | $1,193,435.45 |
DisclosureSEC source: 0001061983-22-000051 · edgardoc.xml · derivative · entry 3 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,715 Underlying: Common Stock · 31,715 shares Expires 2032-03-01 F2 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant. Read SEC document |
| March 02, 2022 Filed Mar 3, 2022 21:39 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantIncentive Stock Option (right to buy) · Derivative | 13,285 | $37.63 Strike: $37.63 | $499,914.55 |
DisclosureSEC source: 0001061983-22-000051 · edgardoc.xml · derivative · entry 2 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,285 Underlying: Common Stock · 13,285 shares Expires 2032-03-01 F2 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant. Read SEC document |
| March 02, 2022 Filed Mar 3, 2022 21:39 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-22-000051 · edgardoc.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,196 F1 · kind: Comprised of restricted stock units that will vest over 3 years, with 40% vesting on the 1-year anniversary of the grant, an additional 40% vesting on the 2-year anniversary of the grant, and the final 20% vesting on the 3-year anniversary of the grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 00:46 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 3,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-22-000024 · edgardoc.xml · nonDerivative · entry 2 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,196 F2 · kind: Comprised of restricted stock units (RSUs) issued upon conversion of certain PSUs granted to the Reporting Person on May 11, 2021. The satisfaction and certification of the performance metric resulted in a portion of the PSUs being converted into RSUs of the Issuer. These RSUs will vest in whole on February 16, 2023. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 00:46 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 1,919 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-22-000024 · edgardoc.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,071 F1 · kind: On or about May 11, 2021, the Reporting Person was granted performance-based stock units (PSUs) of the Issuer, which upon satisfaction and certification of the performance metric resulted in a portion of the PSUs being converted into fully-vested shares of common stock of the Issuer. Read SEC document |
| March 31, 2021 Filed Apr 5, 2021 21:46 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 150,000 | $23.26 Strike: $23.26 | $3,489,000.00 |
DisclosureSEC source: 0001061983-21-000095 · edgardoc.xml · derivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officers 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-03-31 F1 · derivative.exercise_date: Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.